Pharmasyntez-Nord Research and Manufacturing Complex, which is a part of the Pharmasyntez Group of Companies, has successfully passed the inspection by the Syrian Ministry of Health for GMP compliance and received an official authorization to supply manufactured drugs to the Syrian Arab Republic.

The commission, consisting of the representatives of the Ministry of Health and pharmaceutical companies of Syria, assessed Pharmasyntez-Nord's manufacturing sites for GMP compliance, as well as compliance with the regulatory requirements of the Ministry of Health of the Syrian Arab Republic. The delegation visited the production of cytostatic drugs, which is currently producing 45 trade names of oncological drugs, 99% of which are included in the list of vital and essential drugs of the Ministry of Health of Russia. Storage areas, laboratories were also inspected, and the necessary documentation was assessed.

During the inspection, an additional check was carried out to ensure compliance with the requirements set by the Ministry of Health of Syria, which in some aspects differ from the standard GMP certification of the Ministry of Industry and Trade of the Russian Federation.

The Pharmasyntez Group of Companies will be one of the first Russian companies to supply to Syria a range of vital drugs, such as antineoplastic, hormonal drugs, vaccines, and antibiotics. The company's production capacity will make it possible to fully cover the state's needs for these drugs. The drug deliveries are expected to start in the near future.

“Entering the Syrian market is a new prospect for the company's export activities in the Middle East. Pharmasyntez is planning to expand the geography of drug supplies to other countries in the region,” said Nikita Punia, Chief Operating Officer of the Pharmasyntez Group of Companies.